These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 34165201)

  • 41. Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
    Schreiber S; Rubin DT; Ng SC; Peyrin-Biroulet L; Danese S; Modesto I; Guo X; Su C; Kwok KK; Jo H; Chen Y; Yndestad A; Reinisch W; Dubinsky MC
    J Crohns Colitis; 2023 Nov; 17(11):1761-1770. PubMed ID: 37402275
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
    Biemans VBC; Sleutjes JAM; de Vries AC; Bodelier AGL; Dijkstra G; Oldenburg B; Löwenberg M; van Bodegraven AA; van der Meulen-de Jong AE; de Boer NKH; Srivastava N; West RL; Römkens TEH; Horjus Talabur Horje CS; Jansen JM; van der Woude CJ; Hoekstra J; Weersma RK; van Schaik FDM; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 May; 51(9):880-888. PubMed ID: 32237087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program.
    Loftus EV; Baumgart DC; Gecse K; Kinnucan JA; Connelly SB; Salese L; Su C; Kwok KK; Woolcott JC; Armuzzi A
    Inflamm Bowel Dis; 2023 May; 29(5):744-751. PubMed ID: 35792493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
    Sands BE; Colombel JF; Ha C; Farnier M; Armuzzi A; Quirk D; Friedman GS; Kwok K; Salese L; Su C; Taub PR
    Inflamm Bowel Dis; 2021 May; 27(6):797-808. PubMed ID: 32870265
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
    Dikranian AH; Gonzalez-Gay MA; Wellborne F; Álvaro-Gracia JM; Takiya L; Stockert L; Paulissen J; Shi H; Tatulych S; Curtis JR
    RMD Open; 2022 May; 8(1):. PubMed ID: 35577477
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
    Curtis JR; Regueiro M; Yun H; Su C; DiBonaventura M; Lawendy N; Nduaka CI; Koram N; Cappelleri JC; Chan G; Modesto I; Lichtenstein GR
    Inflamm Bowel Dis; 2021 Aug; 27(9):1394-1408. PubMed ID: 33324993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upfront tofacitinib in patients with biological-naïve ulcerative colitis - An Indian multicentric experience.
    Giri S; Bhrugumalla S; Kamuni A; Mishra D; Pati GK; Agrawal D; Verma G; Wagh R; Chauhan S; Ingle M; Chandnani S; Jain S; Rathi PM; Shukla A; Kale A
    Indian J Gastroenterol; 2024 Feb; 43(1):237-243. PubMed ID: 37726491
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
    Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
    J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
    Sands BE; Long MD; Reinisch W; Panés J; Loftus EV; Nduaka CI; Soonasra A; Mundayat R; Lawendy N; Chan G; Friedman GS; Su C
    Inflamm Bowel Dis; 2022 Feb; 28(2):234-245. PubMed ID: 33742652
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
    Lair-Mehiri L; Stefanescu C; Vaysse T; Laharie D; Roblin X; Rosa I; Treton X; Abitbol V; Amiot A; Bouguen G; Dib N; Fumery M; Pariente B; Carbonnel F; Peyrin-Biroulet L; Simon M; Viennot S; Bouhnik Y
    Dig Liver Dis; 2020 Mar; 52(3):268-273. PubMed ID: 31732444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
    Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
    United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association Between Smoking Status and the Efficacy and Safety of Tofacitinib in Patients with Ulcerative Colitis.
    Rubin DT; Torres J; Regueiro M; Reinisch W; Prideaux L; Kotze PG; Tan FH; Gardiner S; Mundayat R; Cadatal MJ; Ng SC
    Crohns Colitis 360; 2024 Jan; 6(1):otae004. PubMed ID: 38425446
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study.
    Singh A; Midha V; Kaur K; Mahajan R; Singh D; Kaur R; Kohli A; Chawla A; Sood K; Bansal N; Sood A
    J Crohns Colitis; 2024 Feb; 18(2):300-307. PubMed ID: 37656880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
    Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
    Winthrop KL; Vermeire S; Long MD; Panés J; Ng SC; Kulisek N; Mundayat R; Lawendy N; Vranic I; Modesto I; Su C; Melmed GY
    Inflamm Bowel Dis; 2023 Jan; 29(1):85-96. PubMed ID: 35648151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
    Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
    Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
    Dalal RS; Sharma PP; Bains K; Pruce JC; Allegretti JR
    Inflamm Bowel Dis; 2024 Mar; 30(3):395-401. PubMed ID: 37209416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis.
    Giles JT; Ogdie A; Gomez Reino JJ; Helliwell P; Germino R; Stockert L; Young P; Joseph W; Mundayat R; Graham D; Ritchlin C
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33452181
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tofacitinib in the treatment of moderate to severe ulcerative colitis in Colombian pediatric patients: Real world experience.
    Parra-Izquierdo V; Frías-Ordoñez JS; Cuadros C; Vargas M; Vera Chamorro JF; Romero Sanchez C; Flórez-Sarmiento C
    Gastroenterol Hepatol; 2024; 47(6):574-581. PubMed ID: 37820832
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.